INEGY 10 MG20 MG TABLETS

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

EZETIMIBE; SIMVASTATIN

Disponible depuis:

MERCK SHARP & DOHME ISRAEL LTD

Code ATC:

C10AA01

forme pharmaceutique:

TABLETS

Composition:

SIMVASTATIN 20 MG; EZETIMIBE 10 MG

Mode d'administration:

PER OS

Type d'ordonnance:

Required

Fabriqué par:

MERCK SHARP & DOHME B.V., THE NETHERLANDS

Groupe thérapeutique:

SIMVASTATIN

Domaine thérapeutique:

SIMVASTATIN

indications thérapeutiques:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH.Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

Date de l'autorisation:

2012-04-30